Clinical studies are evaluating gene therapies as potential treatment options for DMD, with delandistrogene moxeparvovec recently granted accelerated approval by the U.S. Food and Drug Administration for use in ambulatory patients aged 4–5 years with a confirmed mutation in the DMD gene11. Here, DMD is linked to Duchenne muscular dystrophy.